Pharnext

Genset

Serono Genetics Institute S.a.

Genset S.a.

Daniel Cohen

Ilya Chumakov

Serguei Nabirochkin

Rodolphe Hajj

Oxana Guerassimenko

Marta Blumenfeld

Lydie Bougueleret

Emmanuel Vial

Mickael Guedj

Laurent Essioux

Bernard Bihain

Klaus-Armin Nave

Aude Milet

Thomas Prukop

Michael Sereda

Mickaël Guedj

Nathalie Cholet

Viviane Bertrand

Esther Graudens

Annick Cohen-Akenine

Nicholas J Schork

Serguei Nabirotchkin

Anthony Brureau

The present invention provides methods for treating, preventing, or delaying the onset of Charcot-Marie-Tooth Disease type 1A (CMT1A), by administering to a subject in need thereof a combination comprising baclofen, sorbitol and naltrexone, or a pharmaceutically acceptable salt thereof.

Early treatment of CMT disease

The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related disorders.

Compositions for treating CMT and related disorders

The present invention relates to compositions and methods for the treatment of Alzheimer's disease and related disorders. More particularly, the invention relates to combined therapies that modulate angiogenesis for treating said disease.

Therapeutic approaches for treating Alzheimer disease and related disorders through a modulation of angiogenesis

The present invention relates to combinations and methods for the treatment of neurological disorders related to amyloid beta toxicity and/or neuronal death and/or glucose-impaired neuronal metabolism. More specifically, the present invention relates to novel combinatorial therapies of Alzheimer's disease, Alzheimer's disease-related disorders, frontotemporal dementia, Parkinson's disease, Lewy body dementia, Huntington's disease, peripheral neuropathies, alcoholism or alcohol withdrawal, neurological manifestations of drug abuse or drug abuse withdrawal, amyotrophic lateral sclerosis, multiple sclerosis, spinal cord injury, epilepsy, traumatic brain injury or brain ischemic events based on baclofen, acamprosate and at least one medium chain triglyceride.

Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders

Compositions and methods for the treatment of Alzheimer's disease and related disorders. More particularly, disclosed are combined therapies that modulate synapse function for treating the disease.

Therapeutic approaches for treating Alzheimer disease and related disorders through a modulation of synapse function

The present invention relates to a homogeneous, stable, and palatable pharmaceutical solution comprising baclofen, sorbitol and naltrexone.

Stable oral solutions for combined API

The present invention relates to combinations and methods for the treatment of neurological disorders related Amyloid beta toxicity and/or neuronal death. More specifically, the present invention relates to novel combinatorial therapies of Alzheimer's disease, Alzheimer's disease related disorders, Parkinson's disease, Lewy body dementia, multiple system atrophy and other related synucleinopathies, Huntington's disease, peripheral neuropathies, alcoholism or alcohol withdrawal, neurological manifestations of drug abuse or drug abuse withdrawal, amyotrophic lateral sclerosis, multiple sclerosis, spinal cord injury, epilepsy, traumatic brain injury or brain ischemic events based on 3-phenylsulfonyl-8-(piperazin-1-yl) quinoline and baclofen and/or acamprosate.

Combinatorial therapies of neurological disorders

The present invention relates to combinatorial therapies and methods for the treatment of Alzheimer's disease or an Alzheimer's disease related disorder based on idalopirdine, baclofen and acamprosate, wherein idalopirdine is provided as suboptimal doses.

Idalopirdine-based combinatorial therapies of Alzheimer's disease

The present invention relates to compositions and methods for the treatment of amyotrophic lateral sclerosis. More specifically, the present invention relates to novel combinatorial therapies for treating amyotrophic lateral sclerosis or a related disorder.

Compositions for treating amyotrophic lateral sclerosis

The present invention relates to compositions and methods for controlling glycaemia in a mammalian in need thereof. The present invention relates to compositions and methods for the treatment of diabetes disease and related disorders. More specifically, the present invention relates to novel therapies or combinatorial therapies of diabetes and related disorders, based on compositions controlling the blood glucose level.

Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level

The present invention relates to compositions and methods for controlling glycemia in a mammalian in need thereof. The present invention relates to compositions and methods for the treatment of diabetes and related disorders. More specifically, the present invention relates to novel therapies or combinatorial therapies for diabetes and related disorders, based on compositions controlling the blood glucose level.

Growing community of inventors

Saint Cloud, France

Daniel Cohen